Phase I Study to Compare Safety and Pharmacokinetics of Afatinib, An Oral Irreversible Erbb Family Blocker, in Non-Cancer Subjects with Hepatic Impairment to Matched Healthy Subjects
Keyword(s):
Phase I
◽
1996 ◽
Vol 51
(3-4)
◽
pp. 215-219
◽
2006 ◽
Vol 17
(3)
◽
pp. 353-358
◽
2013 ◽
Vol 33
(6)
◽
pp. 419-427
◽
2009 ◽
Vol 49
(6)
◽
pp. 700-709
◽